Brief: Inhibikase Therapeutics Announces Full Outcomes Of Its Pre-NDA Meeting With The FDA For Ikt-001Pro
28/02/2024 22:37
Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES FULL OUTCOMES OF ITS
PRE-NDA
MEETING WITH THE FDA FOR IKT-001PRO
Source text for Eikon: ID:nGNXbbKrrs
Further company coverage: IKT.O
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary